Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose is to see how quickly two different types of prostate cancer participants respond
when taking enzastaurin.
Cohort 1 - asymptomatic participants with androgen-independent prostate-specific antigen
(PSA)-progressive disease without clinical or radiographic evidence of metastatic disease.
Cohort 2 - participants with androgen-independent metastatic prostate cancer (documented bone
or soft tissue metastases) with rising PSA, clinical, radiographic disease progression
following one prior docetaxel-based regimen